Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease

Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525(1):36–44CrossRefPubMed

Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27(12):1029–1034CrossRefPubMed

Aluf Y, Vaya J, Khatib S, Finberg JP (2011) Alterations in striatal oxidative stress level produced by pharmacological manipulation of dopamine as shown by a novel synthetic marker molecule. Neuropharmacology 61(1–2):87–94CrossRefPubMed

Aluf Y, Vaya J, Khatib S, Loboda Y, Finberg JP (2013) Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway. Neuropharmacology 65:48–57CrossRefPubMed

Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R et al (2007) Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 32(5):1011–1020CrossRefPubMed

Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res 5(3):165–176CrossRefPubMed

Asanuma M, Miyazaki I, Murakami S, Diaz-Corrales FJ, Ogawa N (2014) Striatal astrocytes act as a reservoir for l-DOPA. PLoS One 9(9):e106362CrossRefPubMedPubMedCentral

Bar Am O, Amit T, Youdim MB (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355(3):169–172CrossRefPubMed

Bar-Am O, Weinreb O, Amit T, Youdim MB (2010) The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem 112(5):1131–1137CrossRefPubMed

Bar-Am O, Gross A, Friedman R, Finberg JP (2012) Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase. Eur J Pharmacol 683(1–3):226–230CrossRefPubMed

Bartl J, Muller T, Grunblatt E, Gerlach M, Riederer P (2014) Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase—a enzyme activity. J Neural Transm (Vienna) 121(4):379–383CrossRef

Bhattacharya KF, Nouri S, Olanow CW, Yahr MD, Kaufmann H (2003) Selegiline in the treatment of Parkinson’s disease: its impact on orthostatic hypotension. Parkinsonism Relat Disord 9(4):221–224CrossRefPubMed

Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti akinetic effect after l-DOPA treatment by an inhibitor of MAO-B, deprenil. J Neural Transm 36(3–4):303–326CrossRefPubMed

Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D et al (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 29(10):1273–1280CrossRefPubMed

Brooks DJ (2008) Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 4(1):39–47CrossRefPubMedPubMedCentral

Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55(3):981–988CrossRefPubMed

Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L et al (2006) Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67(7 Suppl 2):S18–S23CrossRefPubMed

Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 57(1):2–12PubMed

Cenci MA, Ohlin KE, Odin P (2011) Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson’s disease. CNS Neurol Disord Drug Targets 10(6):670–684CrossRefPubMed

Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL et al (2017) Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study. J Neurol 264(6):1254–1263CrossRefPubMedPubMedCentral

Chang Y, Wang LB, Li D, Lei K, Liu SY (2017) Efficacy of rasagiline for the treatment of Parkinson’s disease: an updated meta-analysis. Ann Med 49(5):421–434CrossRefPubMed

Chen JJ, Swope DM, Dashtipour K (2007) Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther 29(9):1825–1849CrossRefPubMed

Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ (1997) Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 63(2):228–234CrossRefPubMedPubMedCentral

Churchyard A, Mathias CJ, Lees AJ (1999) Selegiline-induced postural hypotension in Parkinson’s disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 14(2):246–251CrossRefPubMed

Culpepper L, Kovalick LJ (2008) A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry 10(1):25–30CrossRefPubMedPubMedCentral

Daws LC (2009) Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 121(1):89–99CrossRefPubMed

deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K et al (2006) Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 21(10):1716–1721CrossRefPubMed

Denney RM, Denney CB (1985) An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and B. Pharmacol Ther 30(3):227–258CrossRefPubMed

Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I et al (2005) Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 14(1):135–143CrossRefPubMed

Edmondson DE, Binda C (2018) Monoamine Oxidases. Sub Cell Biochem 87:117–139CrossRef

Edmondson DE, Binda C, Wang J, Upadhyay AK, Mattevi A (2009) Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 48(20):4220–4230CrossRefPubMedPubMedCentral

Eigeldinger-Berthou S, Meier C, Zulliger R, Lecaude S, Enzmann V, Sarra GM (2012) Rasagiline interferes with neurodegeneration in the Prph2/rds mouse. Retina 32(3):617–628CrossRefPubMed

Eisenhofer G, Kopin IJ, Goldstein DS (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56(3):331–349CrossRefPubMed

Ekblom J, Jossan SS, Bergstrom M, Oreland L, Walum E, Aquilonius SM (1993) Monoamine oxidase-B in astrocytes. Glia 8(2):122–132CrossRefPubMed

Ferreira JJ, Rocha JF, Falcao A, Santos A, Pinto R, Nunes T et al (2015) Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol 22(5):815–825, e856CrossRefPubMed

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154–165CrossRefPubMed

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B et al (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90(21):e1849–e1857CrossRefPubMed

Finberg JP (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 143(2):133–152CrossRefPubMed

Finberg JP, Gillman PK (2011) Selective inhibitors of monoamine oxidase type B and the “cheese effect”. In: Youdim MB, Riederer P (eds) International review of neurobiology, vol 100. Academic Press, Burlington, pp 169–190

Finberg JP, Rabey JM (2016) Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol 7:340CrossRefPubMedPubMedCentral

Finberg JP, Tenne M (1982) Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 77(1):13–21CrossRefPubMedPubMedCentral

Finberg JP, Youdim MB (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43(7):1110–1118CrossRefPubMed

Finberg JP, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS (1995) Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of l-DOPA in hemiparkinsonian rats. J Neurochem 65(3):1213–1220CrossRefPubMed

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K et al (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33(8):1248–1266CrossRefPubMed

Frakey LL, Friedman JH (2017) Cognitive effects of rasagiline in mild-to-moderate stage Parkinson’s disease without dementia. J Neuropsychiatry Clin Neurosci 29(1):22–25CrossRefPubMed

Gallagher IM, Clow A, Glover V (1998) Long-term administration of (−)-deprenyl increases mortality in male Wistar rats. J Neural Transm Suppl 52:315–320CrossRefPubMed

Gerlach M, van den Buuse M, Blaha C, Bremen D, Riederer P (2004) Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch Pharmacol 370(5):388–394CrossRefPubMed

Giladi N, Asgharnejad M, Bauer L, Grieger F, Boroojerdi B (2016) Rotigotine in combination with the MAO-B inhibitor selegiline in early Parkinson’s disease: a post hoc analysis. J Parkinson’s Dis 6(2):401–411CrossRef

Gillman PK (2011) Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol 31(1):66–74CrossRefPubMed

Glezer S, Finberg JP (2003) Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur J Pharmacol 472(3):173–177CrossRefPubMed

Goldberg JF, Thase ME (2013) Monoamine oxidase inhibitors revisited: what you should know. J Clin Psychiatry 74(2):189–191CrossRefPubMed

Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R et al (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J Neurochem 126(5):591–603CrossRefPubMedPubMedCentral

Goldstein DS, Kopin IJ, Sharabi Y (2014) Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther 144(3):268–282CrossRefPubMedPubMedCentral

Goren T, Adar L, Sasson N, Weiss YM (2010) Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol 50(12):1420–1428CrossRefPubMed

Guay DR (2006) Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson’s disease. Am J Geriatr Pharmacother 4(4):330–346CrossRefPubMed

Jankovic J, Berkovich E, Eyal E, Tolosa E (2014) Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord 20(6):640–643CrossRefPubMed

Jarrott B, Iversen LL (1971) Noradrenaline metabolizing enzymes in normal and sympathetically denervated vas deferens. J Neurochem 18(1):1–6CrossRefPubMed

Jenner P, Langston JW (2011) Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord 26(13):2316–2323CrossRefPubMed

Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17(7):1285–1297CrossRefPubMed

Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and l-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60(1):137–144CrossRefPubMed

Katsaiti I, Nixon J (2018) Are there benefits in adding catechol-O methyltransferase inhibitors in the pharmacotherapy of Parkinson’s disease patients? A systematic review. J Parkinson’s Dis 8(2):217–231CrossRef

Kieburtz K (2009) ADAGIO misses a beat? Lancet Neurol 8(12):1081–1082CrossRefPubMed

Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (−)deprenyl. Mech Ageing Dev 46(1–3):237–262CrossRefPubMed

Knoll J (1992) (−)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. J Am Geriatr Soc 40(8):839–847CrossRefPubMed

Knoll J (1998) (−)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82(2):57–66CrossRefPubMed

Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408PubMed

Knoll J, Miklya I (2016) Longevity study with low doses of selegiline/(−)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP). Life Sci 167:32–38CrossRefPubMed

Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155(1):154–164PubMed

Knoll J, Miklya I, Knoll B (2002) Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(−)-1-(benzofuran-2-yl)-2-propylaminopentane, (−)-BPAP. Life Sci 71(18):2137–2144CrossRefPubMed

Kumagae Y, Matsui Y, Iwata N (1991) Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol 55(1):121–128CrossRefPubMed

Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F et al (1997) High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson’s disease. Neurosci Lett 221(2–3):202–204CrossRefPubMed

Kuoppamaki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J et al (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65(5):443–455CrossRefPubMed

Kuoppamaki M, Leinonen M, Poewe W (2015) Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off. J Neural Transm (Vienna) 122(12):1709–1714CrossRef

Lader MH, Sakalis G, Tansella M (1970) Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia 18(1):118–123CrossRefPubMed

Lamensdorf I, Youdim MB, Finberg JP (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67(4):1532–1539CrossRefPubMed

Lang AE, Espay AJ (2018) Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord 33(5):660–677CrossRefPubMed

Laux G (1993) Do MAO-B inhibitors have any role in the treatment of depression. In: Szelenyi I (ed) Inhibition of monoamine oxidase B. Birkhauser Verlag. Basel, pp 319–326CrossRef

Lei D, Shao Z, Zhou X, Yuan H (2018) Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. Oncotarget 9(15):12137–12153CrossRefPubMedPubMedCentral

Levitt P, Pintar JE, Breakefield XO (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79(20):6385–6389CrossRefPubMed

Levkovitch-Verbin H, Vander S, Melamed S (2011) Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats. J Glaucoma 20(5):273–277CrossRefPubMed

Lin CH, Fan JY, Lin HI, Chang CW, Wu YR (2018) Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson’s disease. Parkinsonism Relat Disord 50:48–53CrossRefPubMed

Lotufo-Neto F, Trivedi M, Thase ME (1999) Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20(3):226–247CrossRefPubMed

Mandel SA, Sagi Y, Amit T (2007) Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem Res 32(10):1694–1699CrossRefPubMed

Mann J, Gershon S (1980) l-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26(11):877–882CrossRefPubMed

Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T et al (1989) A controlled study of the antidepressant efficacy and side effects of (−)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46(1):45–50CrossRefPubMed

Mannisto PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51(4):593–628PubMed

Mannisto PT, Tuomainen P, Tuominen RK (1992) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br J Pharmacol 105(3):569–574CrossRefPubMedPubMedCentral

Mannisto PT, Lang A, Rauhala P, Vasar E (1995) Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and l-dihydroxyphenylalanine in rat models of depression. Eur J Pharmacol 274(1–3):229–233CrossRefPubMed

Marin C, Aguilar E, Bonastre M, Tolosa E, Obeso JA (2005) Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol 192(1):184–193CrossRefPubMed

Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78(4):727–735CrossRefPubMed

Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M (2002) Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24(5):675–682CrossRefPubMed

Mendis N, Pare CM, Sandler M, Glover V, Stern GM (1981) Is the failure of (−)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology 73(1):87–90CrossRefPubMed

Montastruc JL, Chaumerliac C, Desboeuf K, Manika M, Bagheri H, Rascol O et al (2000) Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol 23(5):271–275CrossRefPubMed

Moreau JL, Borgulya J, Jenck F, Martin JR (1994) Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol 5(3):344–350CrossRefPubMed

Mosnaim AD, Hudzik T, Wolf ME (2015) Behavioral effects of beta-phenylethylamine and various monomethylated and monohalogenated analogs in mice are mediated by catecholaminergic mechanisms. Am J Ther 22(6):412–422CrossRefPubMed

Mostile G, Nicoletti A, Dibilio V, Luca A, Raciti L, Sciacca G et al (2017) Switching l-DOPA therapy from pulsatile to pulse administration reduces motor complications in Parkinson’s disease. Clin Neuropharmacol 40(1):6–10PubMed

Muller T (2015) Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs 75(2):157–174CrossRefPubMed

Muller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm (Vienna) 120(5):761–765CrossRef

Muller T, Riederer P, Grunblatt E (2017) Determination of monoamine oxidase A and B activity in long-term treated patients with Parkinson disease. Clin Neuropharmacol 40(5):208–211CrossRefPubMed

Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PDSG (2007) Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68(1):45–50CrossRefPubMed

Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M et al (2018) Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology 90(8):e664–e672CrossRefPubMedPubMedCentral

Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson’s disease. Neurobiol Dis 38(1):136–143CrossRefPubMed

Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2011) Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson’s disease. Neurobiol Dis 41(2):585–590CrossRefPubMed

O’Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322(3):198–202CrossRefPubMed

Olanow CW (2006) Rationale for considering that propargylamines might be neuroprotective in Parkinson’s disease. Neurology 66(10 Suppl 4):S69–S79CrossRefPubMed

Olanow CW, Myllyla VV, Sotaniemi KA, Larsen JP, Palhagen S, Przuntek H et al (1998) Effect of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology 51(3):825–830CrossRefPubMed

Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G et al (2006) TCH346 as a neuroprotective drug in Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 5(12):1013–1020CrossRefPubMed

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361(13):1268–1278CrossRefPubMed

Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M et al (2013) Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071CrossRef

Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA et al (2017) A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson’s disease. Mov Disord 32(5):783–789CrossRefPubMed

Petit GH, Berkovich E, Hickery M, Kallunki P, Fog K, Fitzer-Attas C et al (2013) Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson’s disease. PLoS One 8(4):e60691CrossRefPubMedPubMedCentral

Pursiainen V, Korpelainen TJ, Haapaniemi HT, Sotaniemi AK, Myllyla VV (2007) Selegiline and blood pressure in patients with Parkinson’s disease. Acta Neurol Scand 115(2):104–108CrossRefPubMed

Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947–954CrossRefPubMed

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW et al (2011) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10(5):415–423CrossRefPubMed

Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V et al (2016) Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord 31(10):1489–1496CrossRefPubMed

Reilly DK, Rivera-Calimlim L, Van Dyke D (1980) Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 28(2):278–286CrossRefPubMed

Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D (1978) Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (−)deprenyl administration. J Neural Transm 43(3–4):271–277CrossRefPubMed

Riederer P, Muller T (2018) Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical-pharmacological aspects. J Neural Transm (Vienna). https://doi.org/10.1007/s00702-018-1876-2 CrossRef

Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R et al (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763–775CrossRefPubMedPubMedCentral

Rocha JF, Ferreira JJ, Falcao A, Santos A, Pinto R, Nunes T et al (2016) Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with parkinson disease. Clin Pharmacol Drug Dev 5(3):232–240CrossRefPubMed

Rodrigues FB, Ferreira JJ (2017) Opicapone for the treatment of Parkinson’s disease. Expert Opin Pharmacother 18(4):445–453CrossRefPubMed

Sader-Mazbar O, Loboda Y, Rabey MJ, Finberg JP (2013) Increased l-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Br J Pharmacol 170(5):999–1013CrossRefPubMedPubMedCentral

Saura J, Bleuel Z, Ulrich J, Mendelowitsch A, Chen K, Shih JC et al (1996) Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 70(3):755–774CrossRefPubMed

Saura J, Andres N, Andrade C, Ojuel J, Eriksson K, Mahy N (1997) Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol Aging 18(5):497–507CrossRefPubMed

Schrempf W, Fauser M, Wienecke M, Brown S, Maass A, Ossig C et al (2018) Rasagiline improves polysomnographic sleep parameters in patients with Parkinson’s disease: a double-blind, baseline-controlled trial. Eur J Neurol 25(4):672–679CrossRefPubMed

Semkova I, Wolz P, Schilling M, Krieglstein J (1996) Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 315(1):19–30CrossRefPubMed

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P et al (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51(5):604–612CrossRefPubMed

Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W et al (2005) Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 20(3):306–314CrossRefPubMed

Solla P, Cannas A, Marrosu F, Marrosu MG (2010) Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat 6:483–490CrossRefPubMedPubMedCentral

Sonsalla PK, Wong LY, Winnik B, Buckley B (2010) The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol 221(2):329–334CrossRefPubMed

Stocchi F, Rabey JM (2011) Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. Eur J Neurol 18(12):1373–1378CrossRefPubMed

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E et al (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18–27CrossRefPubMed

Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V et al (2012) A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord 27(1):106–112CrossRefPubMed

Szoko E, Tabi T, Riederer P, Vecsei L, Magyar K (2018) Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease. J Neural Transm (Vienna). https://doi.org/10.1007/s00702-018-1853-9 CrossRef

Tatton W, Chalmers-Redman G RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (−)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47(Supplement 3):S171–S183CrossRefPubMed

Thebault JJ, Guillaume M, Levy R (2004) Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 24(10):1295–1305CrossRefPubMed

Tipton KF (2018) 90 years of monoamine oxidase: some progress and some confusion. J Neural Transm (Vienna). https://doi.org/10.1007/s00702-018-1881-5 CrossRef

Vaya J, Aluf Y, Finberg JPM (2012) Oxidative stress in Parkinson’s disease. In: Gadoth N, Gobel HH (eds) Oxidative stress and free radical damage in neurology. Springer, New York, pp 191–224

Wachtel SR, Abercrombie ED (1994) l-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63(1):108–117CrossRefPubMed

Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 1053:348–355CrossRefPubMed

Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230(4722):181–183CrossRefPubMed

Westlund KN, Denney RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25(2):439–456CrossRefPubMed

Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T et al (2001) Human l-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514(2):291–302CrossRefPubMed

Youdim MB, Gross A, Finberg JP (2001a) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132(2):500–506CrossRefPubMedPubMedCentral

Youdim MB, Wadia A, Tatton W, Weinstock M (2001b) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939:450–458CrossRefPubMed

Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295–309CrossRefPubMed

Yu PH, Hertz L (1983) Type A and B monoamine oxidase in glial cells in long-term culture. Prog Neuropsychopharmacol Biol Psychiatry 7(4–6):687–690CrossRefPubMed

At a glance: The STEP trials

Springer Medicine

Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder

Dopamine in psychiatry: a historical perspective

Classical dopamine agonists

Tyrosine-hydroxylase immunoreactivity in the mouse transparent brain and adrenal glands

Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment

Dopaminergic modulation of striatal function and Parkinson’s disease